PET scan to see graft-versus-host disease activity
Part of Immune system & allergy clinical trials.
This study tests a new PET imaging agent to see if it can show areas of graft-versus-host disease (GVHD) in the body. If it works, it might help doctors better understand and manage GVHD after a stem cell transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with acute or chronic graft-versus-host disease (GVHD).
- You are 18 years or older.
- You are able to give written consent to participate.
- Your kidney function is adequate (creatinine clearance of at least 30).
- You may be planning to start a new treatment for GVHD, or you may already be on treatment.
- You are willing to use effective birth control during the study (if applicable).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new imaging scan (called 18F-FAPI PET/CT) that may help detect scarring in the lungs, heart, or blood vessels. If you have a heart, lung, or blood vessel condition that could cause scarring, this scan might show damage earlier and help doctors plan better treatment.
This trial tests a special PET scan that tracks immune activity to see if it can help monitor how well immunotherapy is working in people with various cancers. It is for patients about to start immunotherapy for the first time.
This early study tests a new PET scan tracer (a radioactive imaging agent) that may light up a cell marker called CXCR4 in certain blood and solid tumor cancers. It may help doctors see where cancers are and how much CXCR4 they have, which could guide future treatments.
This trial uses a special PET scan (68Ga-grazytracer) to see how well immunotherapy is working in people with advanced liver or bile duct cancer. The goal is to find a better way to monitor treatment response.
This trial uses a special PET scan to see how well your breast cancer is responding to neoadjuvant therapy (treatment given before surgery). The goal is to help doctors personalize your care by checking if the cancer is shrinking.
This study uses a special PET scan to see how a new imaging agent behaves in the body. It is for healthy people to help future research on inflammation.
Hear when a new Pilot Study trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.